BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...

The gross proceeds from the offering are expected to be approximately $3.13 million, excluding any proceeds that may be received upon exercise of the warrants and before deducting the placement ...

The company plans to use the proceeds to support exploration at the Lunahuasi project in Argentina and the Los Helados ...

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...

Bioscience Corp. (Nasdaq:LEXX; LEXXW), a developer of drug delivery platforms, today announced that it has closed a ...

Information on the total number of voting rights and sharesGhent, BELGIUM, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Press Release Regulated information (Euronext Brussel : BTLS) (the “Company” or “Biotalys” ...

Information on the total number of voting rights and sharesGhent, BELGIUM, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Press Release Regulated information Biotalys NV) (the "Company" or "Biotalys"), an ...

The Offering was conducted in reliance upon available exemptions from the prospectus requirements of applicable Canadian ...

The Company will use the proceeds of the Offering to fund the advancement of the Company's Preliminary Economic Study on its wholly owned 100% owned high-grade Perron Gold Project and general working ...

The proceeds from both the public offering and private placement are earmarked for general ... and Exchange Commission (SEC), including a base prospectus and a prospectus supplement related ...

NGEx Minerals Ltd. ("NGEx Minerals" "NGEx" or the "Company") (TSX: NGEX) (OTCQX: NGXXF) is pleased to announce that due to ...

Detailed price information for Strikepoint Gold Inc (SKP-X) from The Globe and Mail including charting and trades.